E. Mathias

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Rachida Lebtahi, Mohamed Bouattour, Christophe Aubé, 2017, The Lancet. Oncology.

Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial.

A. Luciani, R. Perdrisot, G. Chatellier, 2017 .

LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial.

A. Luciani, R. Perdrisot, G. Chatellier, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.